Skip to main content

Table 1 Transition probabilities

From: Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis

From

To

Stage 1

Stage 2

Stage 3

Stage 4

Death

Stage 1

0.677

0

0

0

0

Stage 2

0.217

0.706

0

0

0

Stage 3

0.064

0.213

0.830

0

0

Stage 4

0.038

0.063

0.118

0.820

0

Death

0.004

0.018

0.052

0.180

1

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172